Solutia Reports Third Quarter 20...(SAFLEX(R) ...)

Date:10/26/2009

SAFLEX(R) production line at the 4 1 - 5 Trenton, Michigan Facility Net charges (gains) related to the closure of 1 (4) - (3) the Ruabon, Wales Facility Net pension plan - - 6 6 settlements Loss related to the sale of the North America - - 6 6 Plastic Products business --- --- --- --- $(1) $2 $16 $17 Interest expense related charges from repayment of German term loan to writeoff unamortized debt issuance and debt - 8 - 8 discount --- --- --- --- $(1) $10 $16 $25 === === === === In 2008, (Gains) and Charges affecting comparability, pre-tax other items including interest are as follows: Three Nine Months Months Ended Ended Sept 30, Sept 30, 2008 2008 (dollars in millions) ---- ---- Charge resulting from the expensing of the step-up in basis of our inventory in
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009